WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2003074467) UREA DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2003/074467    International Application No.:    PCT/CA2003/000265
Publication Date: 12.09.2003 International Filing Date: 25.02.2003
Chapter 2 Demand Filed:    15.09.2003    
IPC:
C07C 311/19 (2006.01), C07C 311/42 (2006.01), C07C 335/12 (2006.01), C07C 335/14 (2006.01), C07D 209/16 (2006.01), C07D 209/20 (2006.01), C07D 213/40 (2006.01), C07D 213/81 (2006.01), C07D 217/12 (2006.01), C07D 317/58 (2006.01), C07D 319/18 (2006.01), C07D 333/20 (2006.01), C07D 405/12 (2006.01), C07D 409/12 (2006.01)
Applicants: PROCYON BIOPHARMA INC. [CA/CA]; 1650 Trans-Canada Highway, Suite 200, Dorval, Québec H9P 1H7 (CA)
Inventors: STRANIX, Brent, Richard; (CA).
BOUZIDE, Abderrahim; (US).
SAUVE, Gilles; (CA)
Agent: KOSIE, Ronald, S.; Brouillette Kosie Prince, 25th Floor, 1100, René-Lévesque Boul. West, Montréal, Québec H3B 5C9 (CA)
Priority Data:
2,374,362 04.03.2002 CA
10/143,095 13.05.2002 US
Title (EN) UREA DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS
(FR) DERIVES DE L'UREE INHIBITEURS DE L'ASPARTYL PROTEASE DU VIH
Abstract: front page image
(EN)The present invention provides HIV aspartyl protease inhibitors of the formula (I): and when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein n is 3 or 4, Y is O, S, NH or N−CN, wherein Cx may be, for example COOH, or CH20H, wherein R1 is selected from the group consisting of a benzenesulfonyl group of formula II as defined herein, wherein R2 may be, for example, iso−butyl, or 3−methylbutyl, and wherein R3 and R4 areas defined herein.
(FR)L'invention porte sur des inhibiteurs de l'aspartyl protéase du VIH, de formule (I), et, lorsque le composé de formule (I) comporte un groupe amino, sur ses sels pharmacocompatibles. Dans ladite formule: n est 3 ou 4; Y est O, S, NH ou N-CN; Cx peut par exemple être COOH ou CH20H; R1 est un groupe benzènesulfonyle de formule (II) tel que défini dans la description; R2 peut par exemple être <i>iso</i>-butyle ou 3-méthylbutyle, et R3 et R4 sont tels que définis dans la description.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)